Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

About this update from Acepodia, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/a0a1a81bd2b72a5021193c01061e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LT09u_DivEgBZtWp6Pyg6A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/a0a1a81bd2b72a5021193c01061e08d3","width":480,"height":480}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs","length":159,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":159,"olType":false},{"type":"text","content":"BEIJING & ALAMEDA, Calif. & TAIPEI, Taiwan, January 09, 2026--(BUSINESS WIRE)--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs).","length":479,"tagName":"p"},{"type":"text","content":"The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreement were not disclosed.","length":470,"tagName":"p"},{"type":"text","content":""This new agreement builds upon our recent co-development collaboration with Acepodia, which has focused on the evaluation and selection of leading bispecific antibody and dual-payload ADC candidates," said Dr. Yuelei Shen, President and CEO of Biocytogen. "Based on the preclinical research conducted to date, we believe that the combination of Biocytogen’s RenLite® platform with Acepodia’s Antibody-Dual-Drugs Conjugation (AD2C) technology offers a compellin...

More updates from Acepodia, Inc.